ClinicalTrials.gg
Not yet recruitingNCT07596667Updated May 19, 2026

Profiling Gingival Crevicular Fluid β-Catenin Level With 8-OHdG and Total Antioxidants Capacity During Healing of Periodontal Pockets: A 3-month Clinical Trial

An interventional study of scaling and root planing in Periodontitis, Adult and Periodontal Diseases, sponsored by Zeyad Nazar. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Zeyad Nazar · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Background: To profile gingival crevicular fluid (GCF) β-Catenin, 8-OHdG, and total antioxidants capacity (TAC) in periodontitis patients during healing of periodontal pockets following non-surgical periodontal therapy (NSPT).Methods: Periodontitis patients (n = 21) will included in this clinical trial. Clinical periodontal parameters will recorded and GCF samples will collected from randomly selected 4-6 mm periodontal pockets at baseline (T0) as well as 4 weeks (T1) and 12 weeks (T2) after NSPT. GCF levels of β-catenin, 8-OHdG, and TAC will be assayed by enzyme linked immunosorbent assay (ELISA).

Read the detailed description

Background: To profile gingival crevicular fluid (GCF) β-Catenin, 8-OHdG, and total antioxidants capacity (TAC) in periodontitis patients during healing of periodontal pockets following non-surgical periodontal therapy (NSPT).Methods: Periodontitis patients (n = 21) will included in this clinical trial. Clinical periodontal parameters will recorded and GCF samples will collected from randomly selected 4-6 mm periodontal pockets at baseline (T0) as well as 4 weeks (T1) and 12 weeks (T2) after NSPT. GCF levels of β-catenin, 8-OHdG, and TAC will be assayed by enzyme linked immunosorbent assay (ELISA).

Keywords: periodontal diseases; periodontal debridement; dental polishing; periodontal pocket

Why is this important?

This research explained the effects of non surgical periodontal treatment for patients with periodontal disease on the epithelial tissue regeneration during the healing process.

Introduction Periodontitis is a destructive disease of tooth-supporting tissues which initiated in response to frank dysbiosis of dental biofilm complemented by aggravated immune response. The hallmark of periodontitis is pathologic deepening of gingival sulci which are transformed into periodontal pockets when the front of dental biofilm advances apically. In such situation, immune responses are initiated within gingival tissue in order to counterattack the pathobionts and its virulent products . Polymorph nuclear cells, mainly neutrophils, are among the principle immune system components responsible for this task via series of biological activities such as phagocytosis and netosis. Prolonged inflammation of periodontal lesions and continuous heavy recruitment of these inflammatory cells leads to the release of oxygen free radicals (ROS) in an escalating pace which overwhelm antioxidant capacity of the host . Overproduction of ROS trigger series of destructive events characterized by increased metabolites of lipid peroxidation, DNA damage and protein damage that led to tissues damage . This shift of oxidative-antioxidant balance towards oxidative stress leads to dramatic changes in the levels of oxidative stress-related molecules such as total antioxidant capacity (TAC) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) . These biomarkers can be clinically detected in oral biofluids such as saliva and GCF with a potential to discriminate between periodontal health and disease .

In healthy periodontium, the gingival sulcus is lined by sulcular epithelium which is continued with the junctional epithelium at sulcus base. The epithelial cells are adherent to each other by range of junctional attachment including desmosomes, adherens junctions, and tight junctions. The integrity of this coherent epithelial cells provides a physical barrier against the ingress of pathobionts to deeper tissues or systemic circulation. Adherens junctions is the predominant cellular junctions which structurally composed of E-cadherin that grouped in extracellular, transmembrane, and intracellular domains. β-catenin forms a complex with E-cadherin, mediating the attachment of intracellular domain of adherens junctions to the cytoskeleton . Persistent inflammation associated with excessive oxidative stress culminating in the tissue compromises epithelial barrier function . Damage of E-cadherin-β-catenin complex leads to the release of β-catenin and its subsequent nuclear translocation; thereby, activating Wnt signaling pathway which is responsible for compromising epithelial phenotype . This notion is supported by detecting elevated level of β-catenin in GCF samples collected from periodontitis patients associated with clinical attachment loss (CAL) in comparison to healthy controls .

The goal of periodontal therapy is to preserve and maintain natural dentition as well as improve oral and systemic health. Non-surgical periodontal therapy (NSPT) considered as gold standard decision to remove biofilm and reduce pathobionts load to restore symbiotic state of oral microbiome and tissue homeostasis . Demand of Successful periodontal therapy depends on improvement in clinical parameters in the term of bleeding on probing (BOP), probing pocket depth (PPD) and CAL . Therefore, this study aimed to track changes in the level GCF of β-catenin ,8-OHdG, and TAC and investigate the association between these biomarkers during the healing period.

Materials and methods Study design This study is a clinical trial involving periodontitis patients who will followed for up to 3 months. The study will conducted from June 2026 to September 2026. The participants will be selected from the pool of patients attending the clinics in the College of Dentistry, University of Babylon. The volunteered patients should sign consent form, which will be collected by the examiner.

Inclusion and exclusion criteria The patients should be ≥ 18 years, have no history of systemic disease, have unstable periodontitis at any stage and grade with at least one moderately deep periodontal pocket (4 - 6 mm) at a single-rooted tooth. The patients were excluded when they were smokers, pregnant or lactating, taking medications which might influence the healing such as corticosteroids and calcium channel blockers, having previous periodontal therapy within the last 3 months, or using antibiotics within 3 months prior to enrolment.

Sample size The required sample size for this study was estimated after considering a reduction in probing pocket depth (PPD) from 7.64 ±1.76 mm to 5.68 ±2.3 mm in shallow pockets [12]. By using G*Power software 3.1, it was estimated that a sample of 17 patients was enough for rejecting the null hypothesis at a power of 0.8 and probability margin of error of 0.05. An extra four patients were invited to participate in this study to avoid any dropout during the follow-up.

Clinical examination and procedure At baseline visit (T0), the selected patients will diagnosed with unstable periodontitis which will defined by the presence of interdental clinical attachment loss (CAL) at ≥ 2 non-adjacent teeth and PPD > 5 mm or 4 mm pockets with bleeding on probing (BOP). In absence of interdental CAL, patients having buccal or oral CAL ≥ 3 mm with PPD > 3 mm detectable at ≥ 2 teeth were also diagnosed as periodontitis [13]. After diagnosis, plaque Index (PI) will used to record presence/absence of dental plaque on 4 sites/tooth with the aid of disclosing agent (EMS®, Switzerland) [14]. Then, BOP, PPD and CAL will recorded at 6 sites/tooth using UNC-15 periodontal probe (PHOENIX®, UK) by a calibrated examiner.

GCF samples will collected from randomly selected sites with periodontal pockets of 4 -6 mm after recording the clinical parameters. Each site will dried using cotton and air blowing by triple syringe. A paper strip (Oraflow Inc.®, New York, USA) will inserted into the selected pocket until feeling slight resistance. After 30 seconds, this pre-weighted paper strip will removed and immediately immersed in an Eppendorf tube (CNWTC/OEM, Jiangsu, China) containing 200 µl phosphate buffer saline (PBS) [15]. Then, the tube containing the strip and PBS will weighted using an electronic balance (JOANLAB®, China). The GCF weight will estimated by subtracting the weight of the tube containing the strip and PBS after sampling from the weights of the dry strip and the tube with PBS before sampling the GCF. Then, the tubes containing GCF samples will saved at -20 °C until further analysis.

After GCF samples collection, patients will receive professional mechanical plaque removal (PMPR) using ultrasonic scaler by the same examiner. Finally, oral hygiene instructions will given to all patients including tooth brushing twice a day and interdental cleaning with an appropriate tool such as interdental brush and dental floss. One week later, root surface debridement (RSD) will performed for all sites with pockets with Gracey curettes (Sakura, YDM®, Japan). Then, all teeth will polished by rubber cups and prophylaxis paste. After 4 weeks (T1) and 12 weeks (T2), all clinical parameters will recorded and GCF samples will recollected as describe above by the same examiner.

Enzyme-linked immunosorbent assay The frozen GCF samples will thawed at room temperature and centrifuged at 4000 RPM for 5 min (Rotofix® 32A, Germany). The optical density will measured at 450 nm and the operator who performed the procedures will blinded to the tested groups. Concentration of 8-OHdG was quantified competitive inhibition enzyme immunoassay technique (USCN®, USA). Sensitivity values was 26.81 pg/ml, with a detection range of 74.07-6.000 pg./ml. ELISA-based sandwich technique will used for quantitative measurement of β-catenin kit (USCN®, USA) with sensitivity values was 5.9 pg./ml and detection range of15.6-1.000 pg/ml. Colorimetric assay facilitated by an ELISA TAC kit (Elabscience®, USA) sensitivity value was 0.62 U/ml with detection range 0.62-190.43 U/ml.

Statistical analysis Data will analyzed using Prism 9 for macOS (Version 9.1.1) and IBM SPSS Statistics (Version 27). Data will presented as frequency, percentage or means (SD). The normality of continuous data will tested using Shapiro-Wilk test. Comparisons among means of variables at different time points will carried out using Friedman test. Dunn's test was used for Post hoc comparison between means of variables at two time points with consideration of adjusting considered p value. Pearson test and linear regression will used to assess the association and possible interactions between the study variables. The significance level will set at p value \< 0.05.

02

Conditions studied

  • Periodontitis, Adult
  • Periodontal Diseases

Keywords

  • periodontitis
  • non surgical periodontal therapy
03

In context

Chronic Periodontitis

378 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.

This study's planned enrollment of 21 is below the median of 46 across 308 interventional studies indexed under Chronic Periodontitis.

Browse Chronic Periodontitis studies →

Lead sponsor

This is the only study on the registry with Zeyad Nazar as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients over 18 years old
  • patients with periodontal pockets depth more than 4 mm

Exclusion criteria

Exclusion criteria:

  • Pregnant women
  • patients taking antibiotic within the last three months
  • Patients with systemic disease ( Diabetes mellitus)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    periodontitis patients with pocket depth

    Procedure: scaling and root planing

Interventions

  • Procedurescaling and root planing

    Periodontitis patients (n = 21) will included in this clinical trial. Clinical periodontal parameters will recorded and GCF samples will collected from randomly selected 4-6 mm periodontal pockets at baseline (T0) as well as 4 weeks (T1) and 12 weeks (T2) after NSPT. GCF levels of β-catenin, 8-OHdG, and TAC will be assayed by enzyme linked immunosorbent assay (ELISA).

06

What researchers measure

Primary outcomes

  1. periodontal pocket depth

    periodontal pocket depth reduction

    Time frame: 3 months

  2. measurement of probing pocket depth (PPD)

    measuring probing pocket depth (PPD)

    Time frame: 3 months

  3. measurement of clinical attachment loss (CAL)

    clinical attachment loss (CAL)

    Time frame: 3 months

Secondary outcomes

  1. GCF levels of β-catenin, 8-OHdG, and TAC will be assayed by enzyme linked immunosorbent assay (ELISA) in which all have the same measuring units

    GCF levels of β-catenin, 8-OHdG, and TAC will be assayed by enzyme linked immunosorbent assay (ELISA) after 3 months

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Vitkov L, Singh J, Schauer C, Minnich B, Krunic J, Oberthaler H, Gamsjaeger S, Herrmann M, Knopf J, Hannig M. Breaking the Gingival Barrier in Periodontitis. Int J Mol Sci. 2023 Feb 25;24(5):4544. doi: 10.3390/ijms24054544. PubMed 36901974 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Nov 2026, 4 months later.

Of 89 non-industry interventional studies with no phase under Chronic Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 24. This study's planned 4 months is below that.

Counting every sponsor, half of 90 studies reached it within 15 months; a quarter within 10 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 19, 2026
StartEst.
Jul 15, 2026
Primary completionEst.
Nov 15, 2026
CompletionEst.
Dec 1, 2026
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07596667
Lead sponsor
Zeyad Nazar
Collaborators
Babylon University
Responsible party
Zeyad Nazar (Assistant Professor, Babylon University) — Sponsor-investigator
First posted
May 19, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Nov 15, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
May 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion